Javascript must be enabled to continue!
Use of CRISPR/Cas9 Gene Editing Methods to Investigate the Mechanism of Trem2-Dependent Gene Expression in Macrophages
View through CrossRef
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a surface receptor expressed in macrophages during tissue injury. This receptor plays a role in driving phagocytosis and dampening inflammation. Because of this, it plays a large part in diseases such as Alzheimer’s disease, liver fibrosis, and metabolic syndrome. Each of these diseases all have a population of TREM2-expressing macrophages that does not exist in healthy tissue. However, the exact pathway in which TREM2 is involved in these diseases is rather unknown. Macrophage gene expression is regulated by a variety of transcription factors such as ATF3 and TFEB. These transcription factors have been suggested to be involved in some of the disease processes mentioned above by RNA-seq or ChIP-seq experiments.The research question we addressed was how these two transcription factors directly affectvtranscription in macrophages, specifically in the TREM2 pathway. CRISPR/Cas9 gene editing was used to generate loss of function alleles for each transcription factor. RNA-seq was then used to compare gene expression to define the gene-specific transcriptional roles of each factor and determine whether they play roles downstream of TREM2 signaling.Results showed that Atf3 knockout had very few genes upregulated or downregulated in the RNA seq compared to Trem2 knockout. Tfeb, on the other hand, had 13 genes in common with Trem2 knockout that were expressed lower than the control and 10 genes in common expressed higher than the control. The Tfeb knockout had no difference in Trem2 expression between the knockout population and control, further providing evidence that Tfeb is located downstream of Trem2. Because Trem2 levels stayed consistent in the Tfeb KO, it is likely that some of the effects of Trem2 on the macrophage disease population genes are directly mediated through Tfeb.
Title: Use of CRISPR/Cas9 Gene Editing Methods to Investigate the Mechanism of Trem2-Dependent Gene Expression in Macrophages
Description:
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a surface receptor expressed in macrophages during tissue injury.
This receptor plays a role in driving phagocytosis and dampening inflammation.
Because of this, it plays a large part in diseases such as Alzheimer’s disease, liver fibrosis, and metabolic syndrome.
Each of these diseases all have a population of TREM2-expressing macrophages that does not exist in healthy tissue.
However, the exact pathway in which TREM2 is involved in these diseases is rather unknown.
Macrophage gene expression is regulated by a variety of transcription factors such as ATF3 and TFEB.
These transcription factors have been suggested to be involved in some of the disease processes mentioned above by RNA-seq or ChIP-seq experiments.
The research question we addressed was how these two transcription factors directly affectvtranscription in macrophages, specifically in the TREM2 pathway.
CRISPR/Cas9 gene editing was used to generate loss of function alleles for each transcription factor.
RNA-seq was then used to compare gene expression to define the gene-specific transcriptional roles of each factor and determine whether they play roles downstream of TREM2 signaling.
Results showed that Atf3 knockout had very few genes upregulated or downregulated in the RNA seq compared to Trem2 knockout.
Tfeb, on the other hand, had 13 genes in common with Trem2 knockout that were expressed lower than the control and 10 genes in common expressed higher than the control.
The Tfeb knockout had no difference in Trem2 expression between the knockout population and control, further providing evidence that Tfeb is located downstream of Trem2.
Because Trem2 levels stayed consistent in the Tfeb KO, it is likely that some of the effects of Trem2 on the macrophage disease population genes are directly mediated through Tfeb.
Related Results
TREM2 knockout, but not the R47H Alzheimer’s variant, reduces neural phagocytosis and survival of human iPSC-derived macrophages
TREM2 knockout, but not the R47H Alzheimer’s variant, reduces neural phagocytosis and survival of human iPSC-derived macrophages
Abstract
BACKGROUND: TREM2 is a microglial cell surface receptor, with risk mutations linked to Alzheimer’s disease (AD), including R47H. Binding of ligands to TREM2 trigge...
Application and Prospect of CRISPR-Cas9 Gene Editing Technology in Agricultural Breeding
Application and Prospect of CRISPR-Cas9 Gene Editing Technology in Agricultural Breeding
Since its inception in 2012, the gene editing technology CRISPR-Cas9 has rapidly become a revolutionary tool in the field of gene editing due to its high efficiency, specificity, a...
THE FUTURE OF MEDICINE: ADVANCING GENE THERAPY WITH CRISPR-CAS9’S EXACT PRECISION IN PEDIATRIC MALES
THE FUTURE OF MEDICINE: ADVANCING GENE THERAPY WITH CRISPR-CAS9’S EXACT PRECISION IN PEDIATRIC MALES
The revolutionary potential of CRISPR-Cas9 in medicine lies in its unparalleled precision in gene editing, heralding a new era for treating genetic disorders. This study focuses on...
Characterization of the first TREM2 small molecule agonist, VG‐3927, for clinical development in Alzheimer’s disease
Characterization of the first TREM2 small molecule agonist, VG‐3927, for clinical development in Alzheimer’s disease
AbstractBackgroundTREM2 is a lipid‐sensing receptor expressed by microglial sub‐populations within neuropathological microenvironments, whose downstream signaling promotes microgli...
A viral guide RNA delivery system for CRISPR-based transcriptional activation and heritable targeted DNA demethylation inArabidopsis thaliana
A viral guide RNA delivery system for CRISPR-based transcriptional activation and heritable targeted DNA demethylation inArabidopsis thaliana
AbstractPlant RNA viruses are used as delivery vectors for their high level of accumulation and efficient spread during virus multiplication and movement. Utilizing this concept, s...
CRISPR therapy: A revolutionary breakthrough in genetic medicine
CRISPR therapy: A revolutionary breakthrough in genetic medicine
Gene editing with CRISPR-Cas9 technology revolutionizes modern medicine by enabling precise DNA modifications. Initially discovered as a bacterial defense mechanism, the Cas9 enzym...
Alzheimer’s disease: A CRISPR/CAS9-mediated therapeutic approach
Alzheimer’s disease: A CRISPR/CAS9-mediated therapeutic approach
The degenerative nature of Alzheimer's disease (AD) and its severe effects on cognitive function present a major challenge to worldwide healthcare systems. CRISPR/Cas9, one of the ...
Fundamentals of CRISPR-Cas9: Gene-editing technology and basic
Fundamentals of CRISPR-Cas9: Gene-editing technology and basic
The CRISPR/Cas9 system provides a robust and multiplexable genome editing tool, enabling researchers to precisely manipulate specific genomic elements and facilitating the elucidat...

